Nexentis Technologies is a small holding company with two business lines: an early-stage oncology drug discovery subsidiary, MitoCareX, and a minority stake in a European solar energy developer, Solterra. MitoCareX is Nexentis's primary focus. It targets mitochondrial carrier proteins (the SLC25A protein family) to develop small molecule therapeutics for cancer, with lead programs in non-small cell lung cancer (NSCLC) and pancreatic cancer. Specifically, MitoCareX is developing compounds to overcome drug resistance to EGFR inhibitors and platinum-based chemotherapy in lung adenocarcinoma — a patient population that nearly universally develops resistance to existing EGFR therapies. MitoCareX's core technology is MITOLINE™, a proprietary algorithm that generates 3D structural models of SLC25A proteins to enable virtual screening of small molecules. MitoCareX has identified one hit compound with in-vitro anti-cancer activity and is running hit-to-lead medicinal chemistry to optimize it. MitoCareX has no revenue and no clinical-stage programs. Its intended business model has two tracks: out-licensing or co-developing drug candidates with pharma partners, and licensing the MITOLINE™ platform directly to pharma and biotech companies. Solterra develops and sells solar PV and battery storage projects in Italy, Poland, and Germany, generating revenue upon project sale rather than long-term operation. Nexentis holds 70% of one Solterra project entity and is involved in battery storage projects in Sicily, where Italy's government-backed MACSE mechanism offers 15-year regulated revenue contracts for large-scale storage projects.